Halozyme Therapeutics
Halozyme, Inc. is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, the investigational drug PEGPH20, applies a unique approach to targeting solid tumors, in animal models. Halozyme has established partnerships with leading pharmaceutical companies, including Roche, Baxalta, , Janssen, AbbVie, Lilly, for its ENHANZE® drug delivery. Halozyme is headquartered in San Diego, California.